PharmaBlock Enters Strategic Partnership with Ascentage Pharma

The new Chemistry and Engineering Technology Center (CETC) is located next to PharmaBlock’s GMP manufacturing site in Shangyu, Zhejiang Province, with an investment of 8 million USD.

The CETC is committed to delivering innovative and green chemistry solutions with a focus on flow chemistry, micropacked bed reaction, biocatalysis, and an array of engineering technologies, including but not limited to separation, crystallization, and application of DCS and process simulation.

 The application of micropacked bed in flow hydrogenation is in the spotlight. Such a niche problem-solving technology, which has been increasingly adopted in the industry, is not only applied in lab scale, but also in pilot and manufacturing scale at PharmaBlock, with a daily output of 100Kg to 1000Kg. The technology is for greener, safer and more efficient process development and manufacturing.

PharmaBlock Sciences (Nanjing), Inc. (300725.SZ), a leading innovative chemistry product and service provider throughout the pharmaceutical R&D process, announced the signing of a strategic partnership agreement with Ascentage Pharma (6855.HK), a globally-focused, clinical-stage biotechnology company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases. The partnership aims to strengthen the strategic cooperation between the two companies in drug development and manufacturing.

As a long-term CDMO partner of Ascentage Pharma, PharmaBlock has witnessed many of its development projects advancing quickly from discovery to preclinical and clinical manufacturing. Under the terms of the agreement, PharmaBlock becomes the preferred CDMO partner of Ascentage Pharma, and the two parties will continue to advance and expand CDMO cooperation for current and future projects. PharmaBlock will fully support Ascentage Pharma to accelerate its novel drug development pipeline with the most sufficient R&D input and manufacturing capacity, along with its innovative technological solutions.

Ascentage Pharma focuses on developing therapeutics that inhibit protein-protein interactions to block apoptosis or programmed cell death. The company has built a pipeline of eight clinical drug candidates, including novel, highly potent Bcl-2, and dual Bcl-2/Bcl-xL inhibitors, as well as candidates aimed at IAP and MDM2-p53 pathways, and next-generation tyrosine kinase inhibitors. Ascentage Pharma is also the only company in the world with active clinical programs targeting all three known classes of key apoptosis regulators. The company is conducting more than 40 Phase I/II clinical trials in the US, Australia, and China. HQP1351, the company’s core drug candidate developed for the treatment of drug-resistant chronic myeloid leukemia (CML), has been granted an Orphan Drug Designation (ODD) and a Fast Track Designation (FTD) by the US Food and Drug Administration (FDA), and an NDA for the drug has been submitted in China. To date, Ascentage Pharma has obtained a total of eight ODDs from the FDA for four of the company’s investigational drug candidates.

Dr. Ming GUO, Co-founder and CEO of Ascentage Pharma, said: "PharmaBlock is a reliable and trusted business partner of Ascentage. We appreciate the dedication and professionalism of the PharmaBlock team. I believe that the strategic partnership between the two companies will definitely help us accelerate the new drug development pipeline towards the commercial stage."

Led by an experienced management and core technical team, PharmaBlock has been providing top-standard development and manufacturing solutions of RSMs, intermediates, and APIs for both the drug development and commercial stages. Taking full advantage of its building block capabilities, along with its know-how in chemistry, process development, analytical development, manufacturing and engineering technologies etc., the team has distinguished itself by showing great skill in tackling challenging chemistry, securing reliable supply, controlling costs, and maintaining full compliance of quality and EHS, etc. To further realize safe, efficient and green process development and manufacturing, PharmaBlock has developed an advanced chemistry and engineering technology platform, featuring flow chemistry, micropacked bed hydrogenation, biocatalysis, heterogeneous catalysis, crystallization, solid state chemistry, etc. Their technology platform has enabled more innovative solutions, with shortened lead time and reduced overall costs for development and manufacturing projects.

“With a rich pipeline of assets with first- and best-in-class potentials, Ascentage Pharma is a leading innovative biotechnology company in China with a global footprint. We are so proud to support companies like Ascentage to discover and develop next generation of medicines much needed by the patients," commented Dr. Haijun Dong, CEO of PharmaBlock.

Nice Insight

Nice Insight, established in 2010, is the research division of That’s Nice, A Science Agency, providing data and analysis from proprietary annual surveys, custom primary qualitative and quantitative research as well as extensive secondary research. Current annual surveys include The Nice Insight Contract Development & Manufacturing (CDMO/CMO), Survey The Nice Insight Contract Research - Preclinical and Clinical (CRO) Survey, The Nice Insight Pharmaceutical Equipment Survey, and The Nice Insight Pharmaceutical Excipients Survey.


PharmaBlock Sciences (Nanjing), Inc. (SZSE:300725)  is a leading provider of innovative chemistry products and services throughout the pharmaceutical R&D and commercial production. Officially operated in 2008, PharmaBlock has rapidly gained recognition for its outstanding capability in the design, synthesis, and supply of novel building blocks for drug discovery use. Upon daily monitoring recent researches and patents in drug R&D and medicinal chemistry, the product portfolio keeps expanding.With more drug R&D projects applying the company’s products advance from discovery to preclinical and clinical research, even into commercialization, PharmaBlock moved on to build up top notch process R&D capabilities, and is providing scale-up synthesis and manufacturing of building blocks and GMP/non-GMP intermediates.